Literature DB >> 29712486

Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments.

Mario Petrillo1, Francesca Patella2, Filippo Pesapane2, Matteo B Suter3, Anna M Ierardi1, Salvatore A Angileri1, Chiara Floridi4, Massimo de Filippo5, Gianpaolo Carrafiello1.   

Abstract

This review focuses upon interactions and potential therapeutic targets in the 'vicious cycle' between hypoxia and neoangiogenesis following treatment of hepatocellular carcinoma with transarterial loco-regional therapies. Biomarkers correlated with angiogenesis have been studied by many authors as prognostic determinants following transarterial intrahepatic therapy. According to these results future therapies directed toward specific factors related to angiogenesis could play a significant role in preventing local tumor recurrence and remote metastasis.

Entities:  

Keywords:  HCC; TACE; TAE; TARE; VEGF; embolotherapy; hypoxia; individualized treatment; neoangiogenesis; sorafenib

Mesh：

Year:  2018        PMID： 29712486     DOI： 10.2217/fon-2017-0739

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  26 in total

Review 1.  Role of secretory clusterin in hepatocarcinogenesis.

Authors:  Min Yao; Miao Fang; Wenjie Zheng; Zhizhen Dong; Dengfu Yao
Journal:  Transl Gastroenterol Hepatol       Date:  2018-08-01

2.  Liposome-Encapsulated Zoledronate Favors Tumor Vascular Normalization and Enhances Anticancer Efficacy of Cisplatin.

Authors:  Xin-Jun Cai; Wei-Dong Fei; Ying-Ying Xu; Hong Xu; Gao-Yi Yang; Jia-Wei Cao; Jian-Jun Ni; Kaiyi Tao; Zeng Wang
Journal:  AAPS PharmSciTech       Date:  2020-01-07       Impact factor: 3.246

3.  Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.

Authors:  Miao Xue; Yanqin Wu; Bowen Zhu; Xinhua Zou; Wenzhe Fan; Jiaping Li
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

4.  Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.

Authors:  Ningjie Li; Jiao Chen
Journal:  Ir J Med Sci       Date:  2022-01-27       Impact factor: 1.568

Review 5.  Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.

Authors:  Khaled Mahmoud; Shady Swidan; Mohamed El-Nabarawi; Mahmoud Teaima
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

6.  Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization.

Authors:  Tongqiang Li; Qin Shi; Jiacheng Liu; Yingliang Wang; Chen Zhou; Chaoyang Wang; Shuguang Ju; Songjiang Huang; Chongtu Yang; Yang Chen; Yaowei Bai; Bin Xiong
Journal:  J Hepatocell Carcinoma       Date:  2021-12-03

Review 7.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

8.  Effect of bead size and doxorubicin loading on tumor cellular injury after transarterial embolization and chemoembolization in a rat model of hepatocellular carcinoma.

Authors:  Andrea C Cortes; Hideyuki Nishiofuku; Urszula Polak; Adeeb A Minhaj; Mirtha S Lopez; Kimihiko Kichikawa; Aliya Qayyum; Elizabeth M Whitley; Rony Avritscher
Journal:  Nanomedicine       Date:  2021-09-24       Impact factor: 6.096

9.  Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization.

Authors:  Hai-Tao Dai; Bin Chen; Ke-Yu Tang; Gui-Yuan Zhang; Chun-Yong Wen; Xian-Hong Xiang; Jian-Yong Yang; Yan Guo; Run Lin; Yong-Hui Huang
Journal:  J Gastrointest Oncol       Date:  2021-06

Review 10.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.